GENOMIC VARIABILITY AND NEURAMINIDASE INHIBITOR DRUG SUSCEPTIBILITY PATTERNS OF INFLUENZA A/H1N1PDM09 STRAINS CIRCULATING IN MOROCCO DURING THE 2015-2016 SEASON Authors: EL Falaki F , BIMOUHEN A, REGRAGUI Z, IHAZMAD H, BAKRI Y AND OUMZIL H
ABSTRACT
Information regarding the genomic variability, and susceptibility profile to antiviral drug resistance are
scarce for influenza A/H1N1pdm09 strains circulating in Morocco. The aims of this study are to
survey genetic changes in the hemagglutinin (HA) and neuraminidase (NA)genes and to
phenotypically assess the antiviral drug resistance (AVR) to neuraminidase inhibitors (NAIs) drugs-
related mutations.
During the 2015-2016 flu season, 1189 nasopharyngeal swabs samples were collected from influenza-
like illness (ILI) and severe acute respiratory illness (SARI) patients in eight sentinel sites distributed
throughout the country. Reactive samples by rRT-PCR were inoculated on MDCK cell-line for virus
isolation. Sequencing and phylogenetic analysis of HA and NA genes were performed to evaluate the
genetic diversity of Moroccan A/H1N1pdm09 strains. AVR screening against two NAIs (oseltamivir
and zanamivir) was performed on MDCK-propagated viruses using the functional neuraminidase
inhibition assay.
Among those 1,189 specimens, 185 were A/H1N1pdm09, 59 A/H3N2, and 30 influenza B. Ninety-six
of the 185 A/H1N1pdm09 propagated strains had a HA titer of at least 1:16 and were subjected to
NAIs assay. Phylogenetic analysis of HA and NA genes revealed that Moroccan A/H1N1pdm09 isolates clustered with the predominate genetic group 6B.1. Several amino acid changes in the
antigenic site were identified: S203T, S189T, K163Q, and S162N (N1 numbering), as well as a unique
S185T in the receptor-binding domain. The NA assay showed no increased resistance (normal
inhibition) against both NAI drugs in all tested isolates.
This study confirms that A/H1N1pdm09 circulating strains in Morocco have undergone genetic
variability and dynamic evolution. Surveillance of viral genetic evolution is important for disease
management and appropriate public health interventions during influenza outbreaks
Keywords: Influenza, Hemagglutinin; Neuraminidase; Neurminidase Inhibitors Publication date: 01/10/2023 https://ijbpas.com/pdf/2023/March/MS_IJBPAS_2023_7518.pdfDownload PDFhttps://doi.org/10.31032/IJBPAS/2023/12.10.7518